The cerebrospinal fluid in multiple sclerosis: far beyond the bands

Area of Science:

• Neurology
• Biochemistry
• Immunology

Background:

• Cerebrospinal fluid analysis is crucial for multiple sclerosis (MS) diagnosis and differential diagnosis.
• Classical findings include pleocytosis, elevated protein, intrathecal immunoglobulin G synthesis, and oligoclonal bands, reflecting disease inflammation.
• Emerging biomarkers are needed for better evaluation of MS activity, progression, and treatment efficacy.

Purpose of the Study:

• To critically evaluate the current literature on key cerebrospinal fluid biomarkers in multiple sclerosis.
• To assess the potential of new biomarkers in refining disease and therapy status evaluation.
• To highlight biomarkers that can inform therapeutic choices, especially in escalating treatment strategies.

Main Methods:

• Literature review of studies on cerebrospinal fluid biomarkers in multiple sclerosis.
• Analysis of classical and novel biomarker findings.
• Critical evaluation of biomarker data in conjunction with clinical and neuroimaging information.

Main Results:

• Classical cerebrospinal fluid findings indicate the inflammatory nature of multiple sclerosis.
• New biomarkers, including chemokine ligand 13, fetuin A, and light neurofilament, demonstrate promising results.
• These novel biomarkers provide valuable information for disease evaluation.

Conclusions:

• Novel cerebrospinal fluid biomarkers offer enhanced insights into multiple sclerosis.
• Biomarker levels, particularly light neurofilament, aid in assessing disease activity and progression.
• Integration of these biomarkers with clinical and neuroimaging data can significantly improve therapeutic decision-making in multiple sclerosis management.